Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma

NCT00185302 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)
DRUG: Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)

Sponsor

Bayer